ArticleNature medicine2011
Targeting the missing links for cancer therapy.
Article in Nature medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Targeting poly(ADP-ribose) polymerase in metastatic prostate cancer: current landscape and future directions.Current opinion in oncology · 2026Review
- Loss of ribonuclease DIS3 hampers genome integrity in myeloma by disrupting DNA:RNA hybrid metabolism.The EMBO journal · 2022Article
- NEM-Tar: A Probabilistic Graphical Model for Cancer Regulatory Network Inference and Prioritization of Potential Therapeutic Targets From Multi-Omics Data.Frontiers in genetics · 2021Article
- Driver network as a biomarker: systematic integration and network modeling of multi-omics data to derive driver signaling pathways for drug combination prediction.Bioinformatics (Oxford, England) · 2019Article
- A simple fluorescent assay for the discovery of protein-protein interaction inhibitors.Analytical biochemistry · 2019Article
- Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor.Clinical and translational science · 2019Article
- Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer.F1000Research · 2019Review
- BRCA2 controls DNA:RNA hybrid level at DSBs by mediating RNase H2 recruitment.Nature communications · 2018Article
- LINK-A promotes cell proliferation through the regulation of aerobic glycolysis in non-small-cell lung cancer.OncoTargets and therapy · 2018Article
- Review
- Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization.Oncotarget · 2016Review
- Ovarian Cancer: Current Treatment and Patient Management.Journal of the advanced practitioner in oncology · 2016Review
- Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.Expert opinion on therapeutic targets · 2016Review
- SPOP the mutation.eLife · 2015Article
- Review
- Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening.BMC cancer · 2014Article
- The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.Cancer prevention research (Philadelphia, Pa.) · 2014Article
- Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors.Oncotarget · 2014Article
- Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.Science translational medicine · 2014Article
- Natural and glucosyl flavonoids inhibit poly(ADP-ribose) polymerase activity and induce synthetic lethality in BRCA mutant cells.Oncology reports · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
21383736What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.